Equities
  • Price (EUR)9.55
  • Today's Change0.150 / 1.60%
  • Shares traded--
  • 1 Year change+9.14%
  • Beta0.9513
Data delayed at least 15 minutes, as of Feb 06 2026 16:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

M3 Inc is a Japan-based company mainly engaged in the provision of services centering on the platform of healthcare. The Company has five business segments. Medical Platforms segment conducts marketing-related businesses in Japan utilizing the Internet and real operations centered on medical employee specialized site m3.com. Evidence Solution segment is involved in the contract research organization (CRO) business that supports clinical development work and research, and site management organization (SMO) business that manages the clinical trial operations. Career Solutions segment is engaged in human resource services for healthcare professionals. Site Solution segment provides operational support for medical institutions and home-visit nursing services. Overseas segment provides services of medical related marketing support, research and careers, utilizing the medical employee specialized sites in the United States, the United Kingdom, China, Korea, India, France, Germany and Spain.

  • Revenue in JPY (TTM)343.77bn
  • Net income in JPY49.59bn
  • Incorporated2000
  • Employees15.36k
  • Location
    M3 Inc10F, Akasaka Intercity, 1-11-44, AkasakaMINATO-KU 107-0052JapanJPN
  • Phone+81 362298900
  • Fax+81 362298922
  • Websitehttps://corporate.m3.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
2413:TYO since
announced
Transaction
value
EWEL IncDeal completed03 Mar 202503 Mar 2025Deal completed-1.28%67.73m
Limbic Digital Media Pty LtdDeal completed25 Feb 202525 Feb 2025Deal completed-14.10%--
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.